Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.65 |
| ▸ | HTR2C | P28335 | 8/20 | 0.65 |
| ▸ | HTR2B | P41595 | 5/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 4/20 | 0.38 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.33 |
| ▸ | INPP5B | P32019 | 1/20 | 0.33 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361303 | 0.92 | HTR2C (0.75) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL23723408 | 0.92 | HTR2C (0.75) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL23723323 | 0.88 | HTR2C (0.50) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL25662706 | 0.80 | HTR2C (0.58) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL23747012 | 0.79 | HTR2C (1.00) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL29405683 | 0.78 | HTR2C (1.00) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL30356554 | 0.78 | HTR2C (1.00) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL23723275 | 0.77 | HTR2A (0.44) | HTR2AHTR2CHTR2BHTR6HDAC1 | |
| SCHEMBL29936591 | 0.76 | HTR2C (0.70) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL23723320 | 0.76 | HTR2C (0.70) | HTR2AHTR2CHTR2BHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118373809-A | Quinoxalinone compound and preparation method, pharmaceutical composition and application thereof | 徐州医科大学 | 2024-07-23 | — | — | CN | claimed |
| CN-109970717-B | 4- (alicyclic pyrimidine/pyridine substituted) amino-1H-3-pyrazolecarboxamide FLT3 inhibitor and application thereof | 中国药科大学 | 2022-10-18 | — | — | CN | claimed |
| EP-4747249-A1 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| CN-114401960-B | Glue degradation agent and using method thereof | NOVARTIS AG (CH) | 2026-05-26 | — | — | CN | disclosed |
| US-20260116901-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2026-04-30 | — | — | US | disclosed |
| US-20260078125-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-03-19 | — | — | US | disclosed |
| US-20250388611-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA, INC. (CA) | 2025-12-25 | — | — | US | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025229624-A2 | NEW CD38 INHIBITORS | NAPA THERAPEUTICS LIMITED (GB) | 2025-11-06 | — | — | WO | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12378266-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| WO-2022136914-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-06-30 | — | — | WO | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-114605344-A | Oxadiazole compound, preparation method and application | 西北农林科技大学 | 2022-06-10 | — | — | CN | disclosed |
| EP-4006039-A1 | FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114401960-A | Glue degradation agent and use method thereof | 诺华股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220073528-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| EP-3958861-A1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-01-27 | — | — | US | disclosed |
| WO-2021155470-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | HTR2A 69/4885HTR2C 74/4885HTR2B 101/4885 |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2A 4/4885HTR2C 7/4885HTR2B 13/4885 |
| US-12378266-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | HTR2A 4/4885HTR2C 7/4885HTR2B 13/4885 |
| US-20220073528-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | HTR2A 3475/4885HTR2C 3262/4885HTR2B 3398/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | HTR2A 2757/4885HTR2C 1491/4885HTR2B 2735/4885 |
| US-20260078125-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK3 | HTR2A 1403/4885HTR2C 587/4885HTR2B 954/4885 |
| US-20250388611-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR6, CNR1, HTR1D | HTR2A 16/4885HTR2C 5/4885HTR2B 28/4885 |
| US-20260116901-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR6, CNR1, HTR2C | HTR2A 13/4885HTR2C 3/4885HTR2B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.